Healthcare & life sciences firms that take strong action before a downturn—and invest during a slump—are more likely to outperform.
People need medical treatment and medicine in good times and bad, but healthcare and life sciences companies are not immune to economic downturns. Our new global survey shows that more than three out of four senior decision-makers in the industry are bracing for a recession. Many hospital systems and other providers are already feeling intense margin pressure caused by inflation in labor and supplies. Pharma and medical device companies may be in stronger positions, but senior leaders are concerned about inflation and supply-chain issues.
Based on our research and experience serving clients across industries, we know that leading companies that take decisive action before a downturn—and find opportunities to invest in growth ahead of a recovery—come out on top. In this brief paper, we lay out the steps senior teams should be taking now to set the stage for outperformance.
How to make the most of a downturn: Healthcare & Life SciencesDownload PDF
How to make the most of a downturn in Healthcare & Life Sciences
Join KPMG January 17 for a webcast focused on how healthcare and life sciences experts can prepare for a potential recession and actions that will strengthen resilience.
KPMG 2023 Healthcare and Life Sciences Investment Outlook
Our 2023 Healthcare and Life Sciences Investment Outlook finds turbulence, and opportunity, in this post-pandemic marketplace.